<DOC>
	<DOCNO>NCT02192294</DOCNO>
	<brief_summary>This open-label , randomize , single-dose , one-cohort , two-sequence , two-period crossover study healthy subject .</brief_summary>
	<brief_title>Absolute Bioavailability Of Bosutinib</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject ( nonchildbearing potential ) . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . Subjects willing able comply schedule visit , treatment plan , laboratory test , accept placement indwell catheter infusion study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy ) . A positive urine drug screen cocaine , tetrahydrocannabinol ( THC ) , opiates/opioids , benzodiazepine amphetamine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Bosutinib</keyword>
	<keyword>absolute bioavailability</keyword>
</DOC>